



Michael Hudecek

MD
University of Würzburg

Academic history

Michael Hudecek , MD, completed his medical training, followed by specialist hematology and oncology training at the University of Leipzig, in Leipzig, Germany. He then completed a post-doctoral fellowship at the Fred Hutchinson Cancer Research Center in Seattle, WA. At present, Dr Hudecek leads an independent translational research lab at the University of Würzburg in Germany.

CAR T-cell therapy

Dr Hudecek’s lab conducts translational research centered around engineering tumor specific chimeric antigen receptor (CAR) T-cells and other novel transformative CAR technologies. In particular, he studies the use of these novel therapies to treat patients with multiple myeloma and acute myeloid leukemia. Dr Hudecek has been involved in clinical trials evaluating many CAR T-cell therapies for patients with multiple myeloma.



Exploring the applications of CAR-Ts beyond hematology and oncology

Michael Hudecek • 2 Feb 2022



CAR-T trials and research at UKW

Michael Hudecek • 2 Feb 2022



Young EBMT & EHA Ambassadors: the basic science behind CAR-Ts

Michael Hudecek • 2 Feb 2022



EBMT-EHA CAR T-cell meeting: all the latest in CAR-T

Michael Hudecek • 2 Feb 2022



CARAMBA-1: a Phase I/IIa trial of autologous SLAMF7 CAR-Ts in multiple myeloma

Michael Hudecek • 2 Feb 2022



Myeloma 2016: Panel discussion on gene modified T-cells

Edward Stadtmauer *et al.* • 22 Apr 2016

JOURNAL PAGES

[Diseases](#)

[Topics](#)

[Medicines](#)

[Trials](#)

[Conferences](#)

[VJ Sessions](#)

[Features](#)

[Podcasts](#)

NEWSLETTER

Receive the latest news and videos from VJHemOnc via email

[SIGN UP](#)



SIGN-UP FOR OUR NEWSLETTER!



Keep up to date with all the latest news with our monthly newsletter

[Subscribe now](#)

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

The content of VJHemOnc is intended for healthcare professionals

[Cookie Policy](#) [Privacy Policy](#) [Terms of Use](#) [Editorial Policy](#)